The stomach is not just a digestive organ. It is a sterilization chamber. Gastric acid, with a pH between 1.5 and 3.5, kills the vast majority of bacteria that enter the body through food and water. This acidic environment is one of the body's most important defenses against microbial colonization of the small intestine. When stomach acid production is reduced or eliminated, that barrier fails. Bacteria that would normally be destroyed survive passage through the stomach and enter the small intestine, where they can establish the overgrowth that defines SIBO. Understanding the role of gastric acid in SIBO prevention is essential for identifying and addressing this often-overlooked root cause.
How stomach acid prevents SIBO
The bactericidal effect of gastric acid is primarily a function of pH. At a pH of 1.5 to 3.5, the normal fasting gastric pH, most bacteria are killed within 15 minutes of entering the stomach. This includes common food-borne pathogens as well as the commensal bacteria that populate the oral cavity and are swallowed continuously throughout the day. The acid environment also activates pepsin, a protein-digesting enzyme that further breaks down bacterial cell structures. Together, acid and pepsin create an environment that very few bacteria can survive.
When gastric pH rises above 4.0, the bactericidal capacity of the stomach drops dramatically. At pH 5.0 or above, many bacteria can survive passage through the stomach entirely. The bacteria that reach the duodenum alive then encounter the small intestine, where conditions are more hospitable: higher pH, nutrient-rich contents, and body temperature. If the other defenses against overgrowth (the migrating motor complex, bile, and the ileocecal valve) are intact, they may prevent colonization. But if any of those defenses are also compromised, SIBO risk compounds.
Proton pump inhibitors: the most common cause of low stomach acid
Proton pump inhibitors (PPIs) are among the most widely prescribed medications worldwide. Omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole work by irreversibly blocking the hydrogen-potassium ATPase enzyme (the proton pump) on parietal cells, reducing gastric acid secretion by up to 90%. PPIs raise the median gastric pH from 1.5-3.5 to 4.0-7.0, fundamentally altering the stomach's capacity to kill bacteria. A meta-analysis by Lo and Chan (2013) found that PPI use was associated with a significantly increased risk of SIBO, with odds ratios ranging from 2 to 8 across different studies.
PPIs are appropriately prescribed for conditions like erosive esophagitis, Barrett's esophagus, Zollinger-Ellison syndrome, and peptic ulcer disease. However, they are widely overprescribed and frequently continued long past their indicated duration. Many patients started on a PPI during a hospital stay or for a short course of reflux symptoms remain on the medication for years without reassessment. This long-term, often unnecessary acid suppression creates a sustained environment conducive to bacterial overgrowth in the small intestine.
H. pylori infection and stomach acid
Helicobacter pylori is a bacterium that colonizes the stomach lining and is present in approximately 50% of the global population. Its effect on stomach acid depends on where in the stomach the inflammation is concentrated. Antral-predominant gastritis (inflammation of the lower stomach) tends to increase acid production, contributing to peptic ulcers. Corpus-predominant gastritis (inflammation of the upper stomach, where parietal cells are concentrated) reduces acid production, leading to hypochlorhydria. Pangastritis (widespread inflammation) can go either way but often progresses toward reduced acid output over time.
Patients with corpus-predominant H. pylori gastritis have reduced gastric acid output that mirrors the effects of PPI use. The combination of H. pylori infection and PPI use is particularly concerning, as both factors independently reduce acid production. Eradication of H. pylori in patients with corpus-predominant gastritis may partially restore acid production, though the degree of recovery depends on the extent and duration of parietal cell damage.
Aging and gastric acid decline
Gastric acid production gradually declines with age. Estimates suggest that 10 to 30% of adults over 60 have hypochlorhydria, with the prevalence increasing further in those over 80. This age-related decline is caused by progressive atrophy of the gastric mucosa and loss of parietal cells. The process is accelerated by chronic H. pylori infection, autoimmune gastritis, and long-term PPI use. Age-related hypochlorhydria may partly explain why SIBO prevalence increases with age and why older adults are more susceptible to bacterial infections of the gastrointestinal tract.
Autoimmune gastritis and pernicious anemia
Autoimmune gastritis is a condition in which the immune system attacks the parietal cells of the stomach, progressively destroying the cells responsible for producing gastric acid and intrinsic factor (necessary for B12 absorption). The result is achlorhydria (complete absence of stomach acid) and pernicious anemia (B12 deficiency anemia). Patients with autoimmune gastritis have among the highest rates of SIBO because the gastric acid barrier is entirely absent. This condition is more common in patients with other autoimmune disorders, including autoimmune thyroid disease and type 1 diabetes.
Signs of low stomach acid and nutrient malabsorption
- Iron deficiency anemia that does not respond adequately to oral iron supplementation. Gastric acid is required for the conversion of ferric iron (Fe3+) to the absorbable ferrous form (Fe2+).
- Vitamin B12 deficiency. Gastric acid and pepsin are needed to release B12 from food proteins. Intrinsic factor (produced by parietal cells) is needed for B12 absorption in the ileum.
- Calcium malabsorption and increased fracture risk. Gastric acid enhances calcium solubility and absorption, particularly from calcium carbonate supplements.
- Bloating and fullness after meals, particularly protein-heavy meals. Inadequate acid reduces pepsin activation, impairing protein digestion.
- Undigested food in stool, particularly fibrous or protein-dense foods.
- Increased susceptibility to foodborne illness due to the loss of the acid barrier.
âšī¸If you have SIBO along with iron deficiency, B12 deficiency, or unexplained osteoporosis, low stomach acid should be investigated as a potential contributing factor. These nutrient deficiencies can be both a consequence of low acid and an early clinical sign of hypochlorhydria.
The PPI-SIBO connection: what to discuss with your doctor
If you are taking a PPI and have been diagnosed with SIBO or have symptoms suggestive of SIBO, the PPI should be reviewed as a potential contributing factor. This does not mean all PPIs should be stopped. Patients with Barrett's esophagus, severe erosive esophagitis, or Zollinger-Ellison syndrome have clear medical indications for continued PPI therapy. But patients who were started on a PPI for mild reflux, functional dyspepsia, or as prophylaxis during a hospital stay should discuss with their prescriber whether the medication is still necessary, whether a lower dose would be sufficient, or whether an H2 receptor antagonist could be substituted.
â ī¸This article is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about a medical condition.